(NASDAQ: TPST) Tempest Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.56%.
Tempest Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast TPST's revenue for 2027 to be $3,121,943,689, with the lowest TPST revenue forecast at $3,121,943,689, and the highest TPST revenue forecast at $3,121,943,689.
In 2028, TPST is forecast to generate $11,009,567,140 in revenue, with the lowest revenue forecast at $11,009,567,140 and the highest revenue forecast at $11,009,567,140.